|
1
|
Guckenberger M, Alongi F, Ricardi U, Scorsetti M, Balermpas P, Livi L, Lievens Y, Braam P, Jereczek- Fossa B, Stellamans K, Ratosa I, Peulen H, Widder J, Ramella S, Verbeke L, Dirix P, Khanfir K, Zilli T, Hemmatazad H, Jeene P, Ivaldi G, Clementel E, Fournier B, Fortpied C, Ost P. OC-0599 Factors associated with SBRT doses in oligometastatic disease: an EORTC/ESTRO OligoCare analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02621-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
|
2
|
Verrijssen A, Huibregtse Bimmel-Nagel C, Cnossen J, Theuws J, Peulen H, van den Berg H, Rijkaart D, Voogt E, Burger P, Rutten H, Dries W. PO-1323 Narrowing the difference in dose delivery for IOERT and IOBT for rectal cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03287-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
|
3
|
Guckenberger M, Ricardi U, Scorsetti M, Balermpas P, Lievens Y, Alongi F, Livi L, Braam P, Jereczek-Fossa B, Stellamans K, Verbeke L, Peulen H, Khanfir K, Ramella S, Zilli T, Geets X, Hemmatazad H, Ivaldi G, Ratosa I, Jeene P, Fournier B, Fortpied C, Ost P. PD-0740 Real-world patient & treatment characteristics of oligometastatic disease: results of OligoCare. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07019-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
4
|
Adebahr S, Liu Y, Colette S, Faivre-Finn C, Ahmad S, Ahmed M, Belderbos J, Andratschke N, Franks K, Geets X, Guckenberger M, Konopa K, Lambrecht M, Lewitzki V, Lievens Y, Pourel N, De Ruysscher D, Dziadziuszko R, Fortpied C, McDonald F, Peulen H, Grosu A, Hurkmans C, Le Pechoux C, Nestle U. OC-0061 EORTC 22113-8113 Lungtech trial on SBRT of central lung tumors. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30481-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
|
5
|
Lambrecht M, Sonke J, Nestle U, Peulen H, Weber D, Verheij M, Hurkmans C. PO-0967: Quality assurance of 4DCT in the EORTC Lungtech trial on SBRT for patients with NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31277-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
6
|
Lambrecht M, Sonke J, Nestle U, Guckenberger M, Peulen H, Weber D, Verheij M, Hurkmans C. EP-2209: Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC Lungtech trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32518-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
|
7
|
Peulen H, Sonke J, Van Werkhoven E, Werner-Wasik M, Grills I, Giuliani M, Hope A, Mantel F, Guckenberger M, Belderbos J. PV-0042: SBRT for peripheral lung tumors >5 cm: first results of the multicenter phase I/II VOLUMES trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30352-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
|
8
|
Giuliani M, Hope A, Guckenberger M, Mantel F, Sonke J, Peulen H, Belderbos J, Werner-Wasik M, Ye H, Grills I. MA 13.09 Toxicity and Second Primary Lung Cancers in Late Survivors Following Lung SBRT. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
|
9
|
Stam B, Peulen H, Guckenberger M, Mantel F, Hope A, Belderbos J, Grills I, Werner-Wasik M, O’Connell N, Sonke J. OC-0399: Dose to heart substructures is associated with non-cancer death after SBRT in stage I NSCLC patients. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31648-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
10
|
Peulen H, Sonke J, Van der Bijl E, Damen E, Belderbos J. PV-0277: SBRT with concurrent chemoradiation in stage III NSCLC: first results of the phase I Hybrid trial. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31526-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
11
|
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. Stereotactic body radiotherapy for central lung tumours: Author reply. Br J Radiol 2015; 88:20150532. [PMID: 26151618 PMCID: PMC4743584 DOI: 10.1259/bjr.20150532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 07/06/2015] [Indexed: 11/05/2022] Open
Affiliation(s)
- S Adebahr
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site, Freiburg, Germany
| | | | - E Shash
- EORTC Headquarters, Brussels, Belgium
| | - M Lambrecht
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - C Le Pechoux
- Department of Radiation Oncoiogy, Gustave Roussy, Paris Sud University, Villejuif, France
| | - C Faivre-Finn
- Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK
| | - D De Ruysscher
- Department of Radiation Oncology, KU Leuven—University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - H Peulen
- Department of Radiation Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - J Belderbos
- Department of Radiation Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - R Dziadziuszko
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | - C Fink
- Department of Radiology, Allgemeines Krankenhaus Celle, Celle, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University of Zurich, Zurich, Switzerland
| | - C Hurkmans
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - U Nestle
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site, Freiburg, Germany
| |
Collapse
|
|
12
|
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88:20150036. [PMID: 25873481 PMCID: PMC4628529 DOI: 10.1259/bjr.20150036] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 04/02/2015] [Accepted: 04/13/2015] [Indexed: 12/16/2022] Open
Abstract
Evidence supports stereotactic body radiotherapy (SBRT) as a curative treatment option for inoperable early stage non-small-cell lung cancer (NSCLC) resulting in high rates of tumour control and low risk of toxicity. However, promising results are mainly derived from SBRT of peripheral pulmonary lesions, whereas SBRT for the central tumours can lead to severe radiation sequelae owing to the spatial proximity to the serial organs at risk. Robust data on the tolerance of mediastinal structures to high-dose hypofractionated radiation are limited; furthermore, there are many open questions regarding the efficiency, safety and response assessment of SBRT in inoperable, centrally located early stage NSCLC, which are addressed in a prospective multicentre study [sponsored by the European Organization for Research and Treatment of Cancer (EORTC 22113-08113-LungTech)]. In this review, we summarize the current status regarding SBRT for centrally located early stage NSCLC that leads to the rationale of the LungTech trial. Outline and some essential features of the study with focus on a summary of current experiences in dose/fraction-toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints are provided.
Collapse
Affiliation(s)
- S Adebahr
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany
| | | | - E Shash
- EORTC Headquarters, Brussels, Belgium
| | - M Lambrecht
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - C Le Pechoux
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
| | - C Faivre-Finn
- Institute of Cancer Sciences, Radiotherapy Related Research, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
| | - D De Ruysscher
- KU Leuven–University of Leuven, University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium
| | - H Peulen
- Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - J Belderbos
- Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - R Dziadziuszko
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | - C Fink
- Department of Radiology, Allgemeines Krankenhaus Celle, Celle, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University of Zurich, Zurich, Switzerland
| | - C Hurkmans
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - U Nestle
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany
| |
Collapse
|
|
13
|
Rossi M, Peulen H, van Tinteren H, Wouters M, Sonke JJ, Baas P, Smit E, Belderbos J. Outcome After Sbrt for Potentially Operable Nsclc Patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv048.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|